Syngene Shares Skyrocket 12% on Profit Turnaround

Syngene International experienced a significant 12% share price increase on October 28, closing at ₹411. This surge followed the company's announcement of a sequential profit turnaround for the September quarter of FY27. The contract research and manufacturing services (CRAMS) firm reported a consolidated net profit of ₹32.2 crore, a notable recovery from a net loss of ₹9 crore in the first quarter of FY27. Revenue from operations also improved by 13% quarter-on-quarter, reaching ₹832.7 crore. Operating EBITDA for the quarter stood at ₹147 crore, with an EBITDA margin of 18%, reflecting improved performance compared to the June quarter. Executive Chairperson Kiran Mazumdar-Shaw emphasized that strengthening its position as an integrated research, development, and manufacturing partner, with a focus on differentiated CDMO capabilities, remains Syngene's strategic priority for long-term growth. Managing Director and CEO Siddharth Mittal reiterated the positive traction in the CDMO business and sequential improvements in profitability. However, year-on-year performance showed a revenue decline of 9% and a decrease in profit from ₹67.1 crore in the September 2025 quarter. This was attributed partly to lower Zoetis revenues and forex hedge losses. The company's stock has faced selling pressure, with prices down 37% year-to-date in 2026 and 24% in 2025.